Bolt Biotherapeutics (BOLT) Cash from Operations (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Cash from Operations of 8023000.0 for Q1 2026, down 12.12% sequentially from 7156000.0 in Q4 2025, and up 39.97% YoY from 5731939.65 in Q1 2025.
Bolt Biotherapeutics (BOLT) Cash from Operations (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Cash from Operations for 7 years, with the latest figure at 8023000.0 in Q1 2026.
- Quarterly Cash from Operations rose 39.97% year-over-year to 8023000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34508000.0 (up 40.4% YoY) and the FY2025 annual result came in at 39850000.0, up 34.98% from the prior year.
- Cash from Operations slipped to 8023000.0 in Q1 2026 per BOLT's latest filing, from 7156000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 7156000.0 in Q4 2025 and troughed at 24314000.0 in Q1 2022.
- A 5-year average of 15011235.29 and a median of 14430000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 421.5% in 2022, then jumped 50.41% in 2025.
- Over 5 years, Cash from Operations stood at 17952000.0 in 2022, then rose by 20.54% to 14265000.0 in 2023, then slipped by 1.16% to 14430000.0 in 2024, then surged by 50.41% to 7156000.0 in 2025, then retreated by 12.12% to 8023000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 8023000.0, 7156000.0, and 9732000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 728.46 Mn |
| 10 | Bolt Biotherapeutics | 5.87 Mn | 5.87 Mn | - | -6.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.54 Mn |
| Jun 30, 2026 | -6.54 Mn |
| Mar 31, 2026 | -8.02 Mn |
| Mar 31, 2026 | -8.02 Mn |
| Dec 31, 2025 | -7.16 Mn |
| Dec 31, 2025 | -7.16 Mn |
| Sep 30, 2025 | -9.73 Mn |
| Sep 30, 2025 | -9.73 Mn |
| Jun 30, 2025 | -9.60 Mn |
| Jun 30, 2025 | -9.60 Mn |
| Mar 31, 2025 | -13.37 Mn |
| Mar 31, 2025 | -13.37 Mn |
| Dec 31, 2024 | -14.43 Mn |
| Dec 31, 2024 | -14.43 Mn |
| Sep 30, 2024 | -13.97 Mn |
| Sep 30, 2024 | -13.97 Mn |
| Jun 30, 2024 | -16.14 Mn |
| Jun 30, 2024 | -16.14 Mn |
| Mar 31, 2024 | -16.75 Mn |
| Mar 31, 2024 | -16.75 Mn |